1987
DOI: 10.1016/s0140-6736(87)92230-6
|View full text |Cite
|
Sign up to set email alerts
|

Cyclosporin in Pulmonary Sarcoidosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
18
0

Year Published

1989
1989
2013
2013

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 22 publications
(18 citation statements)
references
References 2 publications
0
18
0
Order By: Relevance
“…In some case reports, it was felt to be effective for refractory disease [156]. In a double-blind, randomised trial of chronic pulmonary sarcoidosis, WYSER et al [22] found no significant additional benefit for adding cyclosporin A to prednisone therapy in terms of either pulmonary function or steroid sparing.…”
Section: Other Agentsmentioning
confidence: 99%
“…In some case reports, it was felt to be effective for refractory disease [156]. In a double-blind, randomised trial of chronic pulmonary sarcoidosis, WYSER et al [22] found no significant additional benefit for adding cyclosporin A to prednisone therapy in terms of either pulmonary function or steroid sparing.…”
Section: Other Agentsmentioning
confidence: 99%
“…Where doses were cited, objective improvement was seen in all five cases, including our own, treated with a high dose range (150-500 ng·ml -1 ) [1,5], but in only 2/16 cases treated with a low dose range (100-200 ng·ml -1 ) [2,4,8]. The dose required to prevent activation of T-cells is lower than that required to inhibit previously activated T-cells.…”
Section: Discussionmentioning
confidence: 67%
“…In 12 patients, a fall in bronchoalveolar lavage lymphocyte count occurred. In two cases, life-threatening endobronchial lesions regressed only with cyclosporin [1,2].…”
Section: Discussionmentioning
confidence: 95%
See 1 more Smart Citation
“…Both patients who had ocular sarcoidosis in this series demonstrated improvement in visual acuity and control of intraocular inflam mation which contrasts with the lack of efficacy of CsA noted in pulmonary sarcoidosis. 25 No patient in our study has discontinued CsA therapy because of toxicity, although the dosage has required modification. The fre quency of relapse remains to be established on cessation of therapy and several patients are now tailing off by monthly decrements of 50 mg. Binder et at.…”
Section: Discussionmentioning
confidence: 93%